Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
about
Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology NursesSubcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyOmacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.
P2860
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@ast
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@en
type
label
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@ast
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@en
prefLabel
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@ast
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
@en
P2093
P2860
P1476
Subcutaneous administration of bortezomib: strategies to reduce injection site reactions
@en
P2093
Carol S Knop
Sandra Kurtin
Todd Milliron
P2860
P304
P356
10.6004/JADPRO.2012.3.6.8
P577
2012-11-01T00:00:00Z